Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when REGENXBIO Inc. publishes a filing, an earnings call transcript or a press release.

Get RGNX alerts

About Steve Pakola

The proxy statement of REGENXBIO Inc. reports total compensation of $3,908,793 for Steve Pakola in fiscal 2019, including a base salary of $305,301. Steve Pakola has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for REGENXBIO Inc. on November 5, 2026. REGENXBIO Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at REGENXBIO Inc. includes Curran M. Simpson (CEO, COO and Board Member), Allan M. Fox (Chairman and Board Member), George Migausky (Chairman and Board Member) and 7 others.

Steve Pakola on recent calls

“I'll begin by speaking to our retina franchise, CuraVeq, which is being developed in both wet AMD and diabetic retinopathy with our partner, Abdi. As we approach top-line data later this quarter, let me review the design of our two pivotal trials, Atmosphere and Ascent.”
Other, Q3 2026 REGENXBIO INC. EARNINGS CONFERENCE CALL ·
“So, you know, as some backdrop, correlation of a surrogate biomarker to an actual benefit or a functional outcome measure is one of the key central tenets that you can think of for accelerated approval.”
Other, Morgan Stanley 24th Annual Global Healthcare Conference ·
“I'll start with the RGX202 program for the treatment of Duchenne. As Curran referenced, we are incredibly excited by the continued momentum we have seen in the Affinity Duchenne clinical program and look forward to initiating BLA submission this quarter.”
Other, REGENXBIO Inc. Q2 FY2026 Earnings Call ·
“I'll start with the RGX202 program for the treatment of Duchenne. As Curran mentioned, we are incredibly excited that enrollment in the Affinity Duchenne Pivotal Trial completed in October 2025.”
Other, REGENXBIO Inc. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at REGENXBIO Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2019 REGENXBIO Inc. (RGNX) $305,301 $3,908,793

Recent activity